Clinical Trial Update: Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma [NA]

View source ↗

Summary

This clinical trial investigates pralatrexate in combination with chidamide as a bridging therapy to allogeneic stem cell transplantation for relapsed or refrac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Pralatrexate (pralatrexate)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | NA | Status: NOT_YET_RECRUITING